Nearly 300 non-invasive diagnostic tests, designed for the detection of various types of cancers, By Roots Analysis

Given the invasive and cost-intensive nature of tissue biopsies, there is a significant unmet need for safer and more patient-friendly cancer diagnostics that are capable of offering highly accurate, and actionable insights related to the disease.

To order this 350+ page report, which features 150+ figures and 200+ tables, please visit this link

• A detailed review of the overall landscape of the non-invasive cancer diagnostics market, featuring information on the developers of such products and analyses based on a number of relevant parameters, such as year of establishment, company size, geographical location, current development status of proprietary liquid biopsy test (under development, research use only, and available), type of product (assay kit, software / algorithm and device), type of tumor marker analyzed (CTCs, ctDNA, cfDNA, exosomes, and others), key applications (early diagnosis, treatment selection, patient monitoring and recurrence monitoring), type of analyte used (blood, urine and others) and target cancer indications.
• An analysis of the various partnerships pertaining to non-invasive cancer diagnostics, which have been established between 2016 and 2019, based on various parameters, such as type of partnership, year of partnership, type of tumor marker, target cancer indications and the most active players.
• An analysis of the investments made in companies engaged in the development of non-invasive cancer diagnostics, including details of seed financing, venture capital financing, debt financing, grants, and capital raised via IPOs and subsequent public offerings.

An analysis of the initiatives of big pharma players, highlighting the key focus areas of such companies and analysis based on various relevant parameters, such as stage of development of their proprietary non-invasive cancer diagnostic test(s), key applications, type of tumor marker and target disease indications

The financial opportunity within the liquid biopsy and other non-invasive cancer diagnostics market has been analyzed across the following segments:

• • Type of Tumor Marker
• ctDNA
• cfDNA
• CTCs
• Exosomes
• Others

• • Application
• Diagnosis / Early Diagnosis
• Patient Monitoring
• Recurrence Monitoring

• • Target Cancer Indication
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Bladder Cancer
• Melanoma
• Gastric Cancer
• Pancreatic Cancer
• Ovarian Cancer
• Others

• End Users
• Hospitals
• Research Institutes
• Others

• Key Geographical Regions
• North America
• Europe
• Asia-Pacific
• Rest of the World

The Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers report features the following companies, which we identified to be key players in this domain:

• Amoy Diagnostics
• DiaCarta
• HaploX Biotechnology
• NeoGenomics
• QIAGEN
• Swift Biosciences
• Sysmex Inostics
• Thermo Fisher Scientific

Press Release: Variation 3 (Format 4)

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Non-Invasive Cancer Screening and Diagnosis
 

5. Market Landscape

6. Company Profiles
 

7. Partnerships and Collaborations

8. Funding and Investment Analysis
 

9. Liquid Biopsy: Initiatives of Big Pharma Players
 

10. Key Acquisition Targets

11. Other Non-Invasive Cancer Diagnostics
 

12. Market Sizing and Opportunity Analysis
 

13. Survey Insights

14. Conclusion
 

15. Executive Insights

16. Appendix 1: Tabulated Data

17. Appendix 2: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]